首页> Cancer> Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

导出 OA

翻译打印收藏纠错

第一作者： Sun Young,Rha

第一单位： Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea.

作者： Sun Young,Rha ^[1] ; Eduardo,Castanon ^[2] ; Sanjeev,Gill ^[3] ; Helene,Senellart ^[4] ; Juanita,Lopez ^[5] ; Iván,Márquez-Rodas ^[6] ; Iván,Victoria ^[7] ; Tae Min,Kim ^[8] ; Zarnie,Lwin ^[9] ; Michael C,Burger ^[10] ; Matteo,Simonelli ^[11] ; Philippe A,Cassier ^[12] ; Andrew E,Hendifar ^[13] ; Paolo A,Ascierto ^[14] ; Corina,Dutcus ^[15] ; Chinyere E,Okpara ^[16] ; Razi,Ghori ^[17] ; Fan,Jin ^[17] ; Roman,Groisberg ^[17] ; Luis,Villanueva ^[18]

作者单位： Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea. ^[1] Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain. ^[2] Medical Oncology Department, Alfred Hospital, Melbourne, Victoria, Australia. ^[3] Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France. ^[4] Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK. ^[5] Hospital General Universitario Gregorio Marañon and Universidad Complutense, Madrid, Spain. ^[6] Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain. ^[7] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ^[8] Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia. ^[9] Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany. ^[10] Department of Biomedical Sciences, Humanitas University, Milan, Italy.;Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy. ^[11] Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France. ^[12] Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA. ^[13] Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy. ^[14] Eisai Inc., Nutley, New Jersey, USA. ^[15] Eisai Ltd., Hatfield, UK. ^[16] Merck & Co., Inc., Rahway, USA. ^[17] Department of Oncology, Instituto Oncologico Fundacion Arturo Lopez Perez, Hospital Clinico Universidad de Chile, Santiago, Chile. ^[18]

关键词 lenvatinib pembrolizumab phase 2 programmed cell death ligand 1 recurrent glioblastoma